A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Apr 12, 2018)
This bill requires the Food and Drug Administration (FDA)to develop guidance regarding how it will assess evidence to support claims of opioid sparing (i.e., the use of drugs that reduce pain while also allowing reduced use or avoidance of oral opioids) for non-opioid or other non-addictive medical products intended to treat pain.
The FDA must also develop guidance regarding how it will consider the misuse and abuse of drugs in making certain determinations of safety.
What just happenedApr 12, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who’s behind it
- Introduced in SenateApr 12, 2018
- Apr 12, 2018IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Apr 12, 2018IntroReferral10000
Introduced in Senate